eyeforpharma – Can payers trust our data?

$0.00

It has been said that data is the new oil and, in truth, data has much in common with the black stuff.

Like oil, data needs to be found and extracted, cleaned and refined, then transported to its final destination – and there are challenges at every point along that journey.

Real-world evidence may be seen as a key fuel to power pharma’s next evolution – from a drug developer/seller to an end-to-end healthcare solutions provider – but it is no simple silver bullet.

Where does the data come from? How reliable is the data? Can pharma even access the best data? Then there’s the analysis – how can pharma ensure that payers trust its analyses? Will payers seek to perform their own analyses, or will they increasingly turn to a third party? If so, which review body will become the most trusted source?

We ask many of these questions in this collection of articles. In Deep Dive (page 4), we discuss the data needs of the new breed of outcome-based contracts. How
can pharma access the datasets to prove the value of a medicine in a payer’s patient population? How comparable are other data sources, and will payers accept them?

Can Payers Trust Our Data? (page 7) examines the trust gap between pharma and payers. How wide is the gap and how can we work in partnership to close it?

In this mini-magazine, we also take a look at two striking trends in pharma today – the burgeoning power of digital health tools (Digital Health Tools Are No Fad, page 10) and the rise and rise of observational studies (Bridging the Evidence Gap, page 12).

I hope you enjoy it.

James Mackintosh

Global Project Director
+44 (0) 207 375 7163jmackintosh@eyeforpharma.com

Description

It has been said that data is the new oil and, in truth, data has much in common with the black stuff.

Like oil, data needs to be found and extracted, cleaned and refined, then transported to its final destination – and there are challenges at every point along that journey.

Real-world evidence may be seen as a key fuel to power pharma’s next evolution – from a drug developer/seller to an end-to-end healthcare solutions provider – but it is no simple silver bullet.

Where does the data come from? How reliable is the data? Can pharma even access the best data? Then there’s the analysis – how can pharma ensure that payers trust its analyses? Will payers seek to perform their own analyses, or will they increasingly turn to a third party? If so, which review body will become the most trusted source?

We ask many of these questions in this collection of articles. In Deep Dive (page 4), we discuss the data needs of the new breed of outcome-based contracts. How
can pharma access the datasets to prove the value of a medicine in a payer’s patient population? How comparable are other data sources, and will payers accept them?

Can Payers Trust Our Data? (page 7) examines the trust gap between pharma and payers. How wide is the gap and how can we work in partnership to close it?

In this mini-magazine, we also take a look at two striking trends in pharma today – the burgeoning power of digital health tools (Digital Health Tools Are No Fad, page 10) and the rise and rise of observational studies (Bridging the Evidence Gap, page 12).

I hope you enjoy it.

James Mackintosh

Global Project Director
+44 (0) 207 375 7163jmackintosh@eyeforpharma.com

%d bloggers like this: